Background: Removal of the plate following Le Fort I osteotomy and BSSO (bilateral sagittal split osteotomy) is a common procedure. However, patients who undergo plate removal experience intense pain and discomfort. This study investigated the half-maximal effective concentration (Ce50) of remifentanil in the prevention of plate removal pain under sedation using dexmedetomidine. Methods: The study evaluated 18 patients, between 18 and 35 years of age, scheduled for elective surgery. Remifentanil infusion was initiated after sedation using dexmedetomidine, and started at a dose of 1.5 ng/mL on the first patient via target-controlled infusion (TCI). Patients received a loading dose of 1.0 μg/kg dexmedetomidine over 10 min, followed by a maintenance dose of 0.7 μg/kg/h. When the surgeon removed the plate, the patient Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score was observed. Results: The Ce of remifentanil ranged from 0.9 to 2.1 ng/mL for the patients evaluated. The estimated effect-site concentrations of remifentanil associated with a 50% and 95% probability of reaching MOAA/S score of 3 were 1.28 and 2.51 ng/mL, respectively. Conclusion: Plate removal of maxilla can be successfully performed without any pain or adverse effects by using the optimal remifentanil effect-site concentration (Ce50, 1.28 ng/mL; Ce95, 2.51 ng/mL) combined with sedation using dexmedetomidine.
INTRODUCTION
Various complications may occur after miniplate and screw fixation, such as infection, plate fracture, nonunion, and mental nerve paralysis or dysesthesia [1] . Plate removal after orthognathic surgery is performed in 1.0%-18.6% of patients [2] . Approximately 80% of the plates are removed within the first year. One of the advantages of the early removal of the plate is that all plates are technically easy to remove and the procedure has low morbidity [2] . However, patients who undergo plate removal procedures without general anesthesia suffer severe pain and anxiety during the surgery. Therefore, there is a need for methods that can reduce the pain, anxiety, and fear experienced by patients.
MAC (monitored anesthesia care) may be useful in minimally invasive surgical procedures such as plate removal. It provides suitable intraoperative conditions for the patient to be comfortable and pain-free. Propofol and Dexmedetomidine has a high specificity for the α 2-receptor and is therefore a complete α2-agonist. It provides outstanding sedation and analgesic effects, with minimal respiratory depression [3] [4] [5] . A recent study showed that dexmedetomidine was an effective sedative drug for patients undergoing a broad range of surgical procedures performed under MAC. As a result, patients were more satisfied after surgery, experienced milder respiratory depression, and opioid use was reduced [6] .
However, the sole use of dexmedetomidine was not as effective as propofol with analgesics for the provision of adequate sedation during the procedure; moreover, dexmedetomidine was associated with significant hemodynamic instability and longer recovery times [7] .
Remifentanil is an ultra-short acting opioid that is quickly hydrolyzed by nonspecific esterases in the plasma and multiple organs [8] . Owing to the fast reaction, short Previous studies have reported that when dexmedetomidine and remifentanil were used together, safe and satisfactory sedation was provided [9, 10] . However, the appropriate concentration of remifentanil during plate removal of maxilla was not suggested. The Ce50 and the Ce 95 are the effective remifentanil effect-site concentrations (Ce) in 50% and 95% of patients for the prevention of emergence of pain or anxiety. Therefore, the goal of our study was to evaluate the Ce 50 of remifentanil for sedation.
MATERIALS AND METHOD

Patient population
After obtaining approval from the Pusan National Table 1 ).
The change between consecutive response and no response was termed a "crossover" with a midpoint concentration between the response and no response
concentrations. This study was ended after eight crossovers had occurred. The eight crossovers were averaged to find the Ce 50 of remifentanil.
Study procedure
No medications were administered prior to the surgery.
A 20-or 22-gauge angiocatheter was inserted into the patient's forearm or the dorsum of the hand for drug injection. When the patient arrived into the operating room, they were connected to the standard monitoring equipment, such as electrocardiography monitor, noninvasive blood pressure measurement devices, and pulse oximetry. Pulse rate and oxygen saturation were conti- The values are the mean ± SD. MBP, mean blood pressure; HR, heart rate; SpO2, oxygen saturation; T0, baseline; T1, after the loading dose of dexmedetomidine was applied and the remifentanil infusion was started; T2, immediately after the plate was removed. nuously monitored from when the patient entered the operating room to discharge from the recovery room.
Non-invasive blood pressure measurements were collected at 5 min intervals during the surgery [11] . After preoxygenation with 5 L/min of 100% oxygen, dexmedetomidine infusion was initiated with a loading dose of 
where Prob is the probability of reaching an MOAA/S score of 3 [15] . 
Statistics
The logistic regression was performed by using NONMEM Therefore, a naïve-pooled data approach was used. Model parameters were estimated by using the option "LIKELIHOOD LAPLACE METHOD=conditional" in NONMEM [15] .
RESULTS
The 18 patients who underwent plate removal surgery were treated dexmedetomidine and remifentanil simultaneously. Each patient's heart rate, mean blood pressure, and oxygen saturation were checked before the remifentanil and dexmedetomidine infusion (baseline, T0), after the loading dose of dexmedetomidine was applied and remifentanil infusion was started (T1), and immediately after the plate was removed (T2) ( Table 3) .
The results of our study showed that there were no complications such as hypotension (decrease in MBP to < 55 mmHg), bradycardia (HR slower than 40 beats/min), oxygen desaturation (SpO 2 below 90%), or respiratory distress.
We found the Ce of remifentanil required to minimize pain during the plate removal procedure. The estimated effect-site concentration of remifentanil associated with a 50% and 95% probability of reaching an MOAA/S score of 3 was 1.28 and 2.51 ng/mL, respectively ( Fig.   1 ).
DISCUSSION
Traditionally, the midazolam-remifentanil regimen has been used for procedures that require sedation. Previous reports have shown that both midazolam-remifentanil and dexmedetomidine-remifentanil ensured the safety of HIFU treatment for uterine fibroids. However, dexmedetomidine-remifentanil provided more stable sedation in patients than the traditional regimen [9] . Another study showed that the dexmedetomidine-remifentanil protocol improved respiratory sparing effects to a greater extent than midazolam-remifentanil. Therefore, the dexmedetomidine-remifentanil regimen can be used safely as a sedation method during endoscopic retrograde cholangiopancreatography (ERCP) [10] .
Our study indicated that the values of MBP, HR, and Heo et al. [14] showed that the Ce 50 and Ce 95 values of remifentanil during cystoscopy when dexmedetomidine was infused at a clinical dose were 1.33 and 1.58 ng/ml, respectively.
In our study, we infused the loading dose of dexmedetomidine for 10 min and remifentanil was started at a dose of 1.5 ng/ml. The dose of remifentanil for the The requirement for fentanyl is reduced by as much as 50%. Clearance is a factor for remifentanil; thus, dose requirements for remifentanil may be reduced even further. However, as the patients enrolled in this study were between 18 and 35 years of age, further study is required to determine the proper concentration of remifentanil in elderly people.
In conclusion, we determined that the Ce50 and Ce95 values of remifentanil, resulting in almost complete abolition of pain during plate removal when using dexmedetomidine at a clinical dose, were 1.28 ng/mL and 2.51 ng/mL, respectively. Therefore, plate removal procedures can be successfully implemented without any pain or adverse effects by using an optimal concentration of remifentanil combined with sedation using dexmedetomidine.
